Introduction
============

Many kidney transplant recipients experience post-transplant hyperuricemia (PTHU).[@b1-dddt-8-245],[@b2-dddt-8-245] Several factors were reported to predispose recipients to hyperuricemia, including insufficient allograft function,[@b3-dddt-8-245] treatment with diuretics, immunosuppression with cyclosporine,[@b4-dddt-8-245] a calcineurin inhibitor (CNI), and immunosuppression with mizoribine.[@b5-dddt-8-245] In the general population, asymptomatic hyperuricemia is a risk factor for the onset and progression of chronic kidney disease and for cardiovascular disease.[@b6-dddt-8-245],[@b7-dddt-8-245] Similarly PTHU is associated with allograft loss and onset of cardiovascular disease in kidney transplant recipients.[@b3-dddt-8-245],[@b8-dddt-8-245]--[@b11-dddt-8-245] Conventional uric acid-lowering therapy consists principally of allopurinol and benzbromarone. Allopurinol inhibits the production of uric acid by inhibiting xanthine oxidase. However, both allopurinol and its active metabolite oxypurinol are excreted in the urine.[@b12-dddt-8-245] Therefore, kidney transplant recipients with chronic kidney disease cannot be administered doses of allopurinol sufficient to lower uric acid. In contrast, benzbromarone increases the urinary excretion of uric acid, but its effects are reduced in transplant recipients with chronic kidney disease, in whom it is difficult achieve target uric acid levels using conventional uric acid-lowering therapy. It has not yet been determined whether uric acid-lowering therapy has beneficial effects on allograft survival rate and the onset of cardiovascular disease in kidney transplant recipients with PTHU.

Febuxostat, a new nonpurine selective xanthine oxidase inhibitor, is well tolerated in patients with gout and in those with mild or moderate renal impairment.[@b13-dddt-8-245]--[@b15-dddt-8-245] However, the efficacy and safety of febuxostat in stable kidney transplant recipients with asymptomatic hyperuricemia has not been assessed. We therefore investigated the efficacy and safety of febuxostat in kidney transplant recipients with PTHU.

Patients and methods
====================

Subjects
--------

We retrospectively analyzed 93 adult kidney transplant recipients who visited Kagawa University Hospital between June 2012 and June 2013. Recipients who were treated with azathioprine and those who underwent kidney transplantation between June 2011 and June 2013 were excluded. The protocols, patient information, and informed consent forms were reviewed and approved by the ethics committee of Kagawa University (H25--052).

Study design
------------

The 93 kidney transplant recipients were treated by four nephrologists and two urologists. PTHU was defined as uric acid ≥7.0 mg/dL (≥0.42 mmol/L) or need for treatment with the conventional uric acid-lowering drugs, allopurinol and benzbromarone. The decision to start treatment with febuxostat was at the discretion of each attending physician.

Of the 93 kidney transplant recipients, 51 were diagnosed with PTHU (PTHU group) and 42 were not (NPTHU group) in June 2012. Of the 51 recipients with PTHU, 26 received febuxostat (FX group) and 25 did not (NFX).

The 26 patients in the FX group were started on febuxostat treatment between May and September 2012. These 26 patients were divided into two subgroups, ie, those who had been treated with conventional uric acid-lowering therapy before treatment with febuxostat (FC subgroup, n=11) and those who had not (FN subgroup, n=15). Of the eleven patients in the FC subgroup, five had received allopurinol (100 mg/day) and six had received benzbromarone (two receiving 25 mg/day and four receiving 50 mg/day). Treatment with febuxostat was started at 10 mg/day and increased to 20 mg/day if serum uric acid levels remained over 7 mg/dL. Of the 26 patients in the FX group, 17 (65%) were finally treated with febuxostat 20 mg/day.

The 25 patients in the NFX group were also divided into two subgroups, ie, those who had been under observation without intervention for PTHU (OB group, n=12) and those who were being continued on conventional uric acid-lowering therapy (CT group, n=13). Of the 13 patients in the CT group, six had received allopurinol (100 mg/day) and seven had received benzbromarone (four receiving 25 mg/day and three receiving 50 mg/day). The type of conventional uric acid-lowering therapy was not switched during the study.

Study entry was defined as the time of starting treatment with febuxostat in the FX group and as June 2012 in the NFX and NPTHU groups. Serum uric acid concentrations were determined at baseline and at one, 3, 6, and 12 months after study entry. One-year changes in serum uric acid (mg/dL per year) were calculated as the concentration at 12 months minus the concentration at baseline. The target uric acid level was set at \<6.0 mg/dL (\<0.36 mmol/L).[@b16-dddt-8-245] The rate of achievement of the target uric acid level (%) was calculated as the number of patients who achieved the target uric acid level divided by the number of patients in that group, and was evaluated at baseline and after 12 months. Rates of achievement of target uric acid levels at baseline and after 12 months were compared individually in the FX and NFX groups, with between-group differences assessed after 12 months.

Allograft function was based on the estimated glomerular filtration rate (eGFR), which was calculated using the Modification of Diet in Renal Disease study equation modified for Japanese individuals.[@b17-dddt-8-245]--[@b19-dddt-8-245] eGFR was measured at baseline and at one and 12 months after entry, with one-year changes in eGFR (mL/min/1.73 m^2^ per year) calculated as the eGFR at 12 months minus the eGFR at baseline. Blood pressure, cell counts (including white blood cells and platelets), hemoglobin concentration, and liver function tests, including serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin concentrations, were measured at baseline and after 12 months. eGFR and blood pressure were compared in the FX and NFX groups. Cell counts, hemoglobin concentration, and liver function were compared in the FX and NFX + NPTHU groups. Severe adverse effects, cardiovascular events, and allograft loss were monitored throughout the study period.

Maintenance immunosuppressive regimens were based principally on combinations of three drugs, ie, tacrolimus or cyclosporine, mycophenolate mofetil or mizoribine, and methylprednisolone. Types of immunosuppressive agents were not switched during the study. Concomitant drugs, including angiotensin II type 1 receptor blockers, calcium channel blockers, proton pump inhibitors, statins and erythropoiesis-stimulating agents, were also checked at baseline. Blood tacrolimus concentrations were determined using a microparticle enzyme immunoassay (IMx™; Abbott Laboratories, Abbott Park, IL, USA).[@b20-dddt-8-245] The dose-normalized tacrolimus blood concentration (ng mL^−1^/0.1 mg kg^−1^)[@b20-dddt-8-245] was evaluated at baseline and at 12 months after entry and was calculated using the formula: trough tacrolimus blood concentration (ng/mL) divided by body weight-normalized tacrolimus dose (0.1 mg/kg), with the latter calculated as 0.1 × tacrolimus dosage (mg)/body weight (kg). To clarify the differences in practice patterns between nephrologists and urologists, the percentages of each starting febuxostat for recipients with PTHU were compared.

Statistical analysis
--------------------

All analyses were performed using Statistical Package for the Social Sciences software version 20.0 for Windows (IBM Japan, Tokyo, Japan). Values are presented as the mean ± standard deviation or number (%). Categorical variables were compared using the χ^2^ test and continuous variables using the Student's *t*-test or one-way analysis of variance. A *P* value\<0.05 was considered to be statistically significant.

Results
=======

Clinical characteristics of the FN, FC, OB, CT, and NPTHU groups
----------------------------------------------------------------

The characteristics of the 93 kidney transplant recipients are shown in [Table 1](#t1-dddt-8-245){ref-type="table"}. Baseline uric acid levels were higher in the FN, FC, and OB groups than in the CT and NPTHU groups. At baseline, smaller percentages of patients in the FN, FC, and OB groups than in the CT and NPTHU groups had achieved target uric acid levels. The percentage of male recipients tended to be higher in the PTHU group than in the NPTHU group. Baseline eGFR tended to be lower in the FN, FC, and CT groups than in the OB and NPTHU groups. There were no significant differences between these groups with regard to age, body mass index, baseline blood pressure, and dose of immunosuppressants. Although rates of administration of angiotensin II type 1 receptor blockers, calcium channel blockers, and erythropoiesis-stimulating agents tended to be higher in the PTHU than in the NPTHU group, there were no significant differences between the FX and NFX groups. Background immunosuppressive drug regimens are shown in [Table 2](#t2-dddt-8-245){ref-type="table"}. The rates of treatment with immunosuppressive drugs were higher in the PTHU (FX + NFX) group than in the NPTHU group, including rates of treatment with mizoribine (24% versus 2%; odds ratio 13.2, 95% confidence interval \[CI\] 1.61--109, *P*\<0.01) and regimens including cyclosporine (26% versus 7%; odds ratio 4.33, 95% CI 1.14--16.5, *P*=0.03). However, there were no differences in background immunosuppressive drug regimens between the FX and NFX groups.

Effects of febuxostat on serum uric acid levels
-----------------------------------------------

The effects of febuxostat on serum uric acid levels are shown in [Table 3](#t3-dddt-8-245){ref-type="table"} and [Figure 1](#f1-dddt-8-245){ref-type="fig"}. Following treatment with febuxostat, serum uric acid levels were lower in the FN and FC groups than in the OB group ([Table 3](#t3-dddt-8-245){ref-type="table"}). The one-year change in serum uric acid levels was significantly greater in the FX group than in the NFX group ([Figure 1A](#f1-dddt-8-245){ref-type="fig"}). Rates of achievement of target uric acid concentration (\<6.0 mg/dL) are shown in [Figure 1B](#f1-dddt-8-245){ref-type="fig"}. In the FX group, this rate was significantly higher after one year of treatment with febuxostat than at baseline (odds ratio 12.0, 95% CI 2.34--61.6, *P*\<0.01). Twelve months after study entry, the rate of achievement of target uric acid levels tended to be higher in the FX group than in the NFX group, but the difference was not statistically significant (odds ratio 3.17, 95% CI 0.96--10.5, *P*=0.08).

Effects of febuxostat on eGFR and blood pressure
------------------------------------------------

The effects of febuxostat on eGFR and blood pressure are shown in [Figure 2](#f2-dddt-8-245){ref-type="fig"}. Although baseline eGFR tended to be lower in the FX group than in the NFX group ([Figure 2A](#f2-dddt-8-245){ref-type="fig"}), the one-year changes in eGFR were similar ([Figure 2B](#f2-dddt-8-245){ref-type="fig"}). Treatment with febuxostat did not affect systolic or diastolic blood pressure ([Figure 2C](#f2-dddt-8-245){ref-type="fig"} and [D](#f2-dddt-8-245){ref-type="fig"}). None of the 93 patients experienced cardiovascular events or allograft loss during the study period.

Effects of febuxostat on liver function, blood cell count, and tacrolimus concentration
---------------------------------------------------------------------------------------

None of the 26 patients in the FX group discontinued treatment with febuxostat, and none experienced severe adverse effects, such as gout attacks or skin rash. Serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin concentrations were similar in the FX and NFX + NPTHU groups ([Figure 3](#f3-dddt-8-245){ref-type="fig"}). The effects of febuxostat on blood cell counts and tacrolimus concentration are shown in [Figure 4](#f4-dddt-8-245){ref-type="fig"}. Changes in white cell count ([Figure 4A](#f4-dddt-8-245){ref-type="fig"}), hemoglobin ([Figure 4B](#f4-dddt-8-245){ref-type="fig"}), and platelets ([Figure 4C](#f4-dddt-8-245){ref-type="fig"}) were similar in the FX and NFX + NPTHU groups. Although dose-normalized tacrolimus blood concentrations tended to be higher in the FX group than in the NFX + NPUHU group, the difference was not statistically significant ([Figure 4D](#f4-dddt-8-245){ref-type="fig"}).

Differences in practice patterns between nephrologists and urologists
---------------------------------------------------------------------

Of the 93 stable kidney transplant recipients, 53 were treated by nephrologists, 25 by urologists, and 15 alternately by both. Of the 26 recipients in the FX group, 25 were treated by nephrologists and one by an urologist. Nephrologists were significantly more likely than urologists to start febuxostat in recipients with PTHU (69% versus 8%, odds ratio 24.2, 95% CI 2.74--214, *P*\<0.01).

Discussion
==========

This study describes an investigation of the efficacy and safety of febuxostat in stable kidney transplant recipients with PTHU. Treatment of these patients with febuxostat significantly decreased serum uric acid concentrations and increased rates of achievement of target uric acid levels without having severe adverse effects.

In contrast with our findings for febuxostat, treatment with allopurinol was shown to be unable to reduce serum uric acid levels sufficiently in stable kidney transplant recipients with PTHU.[@b21-dddt-8-245] Patients with chronic kidney disease and hyperuricemia treated with febuxostat had an increased rate of achievement of target uric acid levels.[@b14-dddt-8-245] Our results also indicate that conversion to febuxostat from conventional uric acid-lowering therapy was effective in lowering uric acid levels in kidney transplant recipients who were unable to achieve sufficiently low serum uric acid levels with conventional therapy. Because some immunosuppressants cause PTHU in kidney transplant recipients,[@b4-dddt-8-245],[@b5-dddt-8-245] decreasing immunosuppressant dosages may reduce the risk of PTHU. However, reducing immunosuppressants may increase the risk of acute rejection in kidney transplant recipients. Our results show that febuxostat could significantly decrease serum uric acid concentrations without reducing the doses of immunosuppressants.

It is unclear whether therapeutic interventions in patients with increased uric acid levels are useful in preventing deterioration of kidney function.[@b22-dddt-8-245]--[@b24-dddt-8-245] Moreover, definitions of hyperuricemia differ widely. In the general population, hyperuricemia is generally defined as a uric acid concentration ≥7.0 mg/dL,[@b25-dddt-8-245] but detailed information is not available for kidney transplant recipients. Guidelines from the KDIGO (Kidney Disease: Improving Global Outcomes) group recommend that hyperuricemia in kidney transplant recipients be treated when there are complications, such as gout, tophi, or uric acid stones.[@b26-dddt-8-245] In this study, urologists followed this recommendation. Conversely, nephrologists tended to treat asymptomatic PTHU because they knew that hyperuricemia was a risk factor for deterioration of kidney function in patients with chronic kidney disease. Although this study was a retrospective cohort study, the differences in practice patterns between nephrologists and urologists enabled comparisons of interventional and observational treatments for asymptomatic kidney transplant recipients with PTHU.

The differences in practice patterns of nephrologists and urologists are not well researched. Nephrologists have been reported to be more likely to treat anemia and mineral bone disease accompanying chronic kidney disease than non-nephrologists.[@b27-dddt-8-245] Another report showed the effects of practice patterns on allograft outcome in pediatric kidney transplantation.[@b28-dddt-8-245] Neither of these studies, however, described differences in practice patterns between nephrologists and urologists in their treatment of hyperuricemia nor the effects of these differences on allograft prognosis. In general, nephrologists are specialized in the management of blood pressure, proteinuria, anemia, and hyperuricemia, whereas urologists are specialized in surgery and treatment with immunosuppressants. Collaborations between nephrologists and urologists may result in better management of stable kidney transplant recipients.

Febuxostat has been reported to have pleiotropic effects on kidney function other than reducing uric acid.[@b29-dddt-8-245] Clinical studies have also shown that allopurinol slows the deterioration of kidney function in patients with chronic kidney disease,[@b6-dddt-8-245],[@b30-dddt-8-245] as well as significantly reducing serum creatinine concentrations in liver transplant recipients with hyperuricemia and renal impairment.[@b31-dddt-8-245] However, no randomized controlled trials have shown that lowering uric acid levels is associated with better allograft survival, allograft function, or recipient survival. Our short-term study showed that lowering uric acid levels was not associated with changes in allograft function or blood pressure. Long-term, large-scale, prospective studies are required to determine whether therapeutic interventions for PTHU can prevent deterioration of allograft function.

No obvious adverse effects were observed in the 26 kidney transplant recipients who received febuxostat. Because febuxostat is a selective xanthine oxidase inhibitor, the combination of febuxostat and azathioprine is not allowed because of their adverse effects on bone marrow.[@b13-dddt-8-245] Recently, azathioprine has been replaced by mycophenolate mofetil or mizoribine as an antimetabolite drug in most kidney transplant recipients. We found no evidence of bone marrow inhibition in any patient who received the combination of febuxostat and mycophenolate mofetil or mizoribine. Tacrolimus concentration has been reported to be associated with broad interindividual pharmacokinetic variability and has been found to be influenced by meals, intestinal edema,[@b20-dddt-8-245] cytochrome P genotype,[@b32-dddt-8-245] and potential interactions with other drugs, such as proton pump inhibitors and calcium channel blockers.[@b33-dddt-8-245],[@b34-dddt-8-245] We found that dose-normalized tacrolimus concentrations tended to be higher in patients who receive febuxostat than in those who did not, although febuxostat does not interact with cytochrome P inhibitors. Additional studies are needed to clarify the effects of febuxostat on tacrolimus concentrations.

This study had several limitations, in particular its small number of patients and its retrospective design. The small sample size of this study may have increased the possibility of type II error. Second, because it was not a randomized controlled study, differences in practice patterns between nephrologists and urologists may have affected our results. Third, baseline eGFR tended to be lower in the FX group than in the NFX group, making it difficult to determine whether lowering of uric acid levels with febuxostat protected allograft function. Finally, the short-term nature of our study precluded determination of the uric acid-lowering effects of febuxostat on cardiovascular events and allograft survival.

In conclusion, our results show that treatment with febuxostat lowers uric acid concentrations sufficiently, without severe adverse effects, in stable kidney transplant recipients with PTHU. Further long-term, larger-scale prospective studies are needed to clarify the effects of febuxostat reduction of uric acid levels on allograft survival and cardiovascular events in stable kidney transplant recipients with PTHU.
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###### 

Recipient characteristics

                                           PTHU                                                                                            FX                                                                                              NFX                                                                                             *P*-value                                                        
  ---------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------- ----------- --------
  Recipients, n                            15                                                                                              11                                                                                              12                                                                                              13                                                   42          
  Baseline uric acid (mg/g Cr)             8.4±1.0[\*](#tfn2-dddt-8-245){ref-type="table-fn"},[†](#tfn3-dddt-8-245){ref-type="table-fn"}   7.5±1.5[\*](#tfn2-dddt-8-245){ref-type="table-fn"},[†](#tfn3-dddt-8-245){ref-type="table-fn"}   7.7±0.6[\*](#tfn2-dddt-8-245){ref-type="table-fn"},[†](#tfn3-dddt-8-245){ref-type="table-fn"}   6.3±1.2                                              5.6±1.0     0.02
  Achievement of target uric acid, n (%)   0                                                                                               2 (18%)                                                                                         0                                                                                               4 (31%)                                              24 (57%)    \<0.01
  Age (years)                              52±12                                                                                           44±10                                                                                           51±18                                                                                           57±9                                                 49±14       0.21
  Male, n (%)                              13 (87%)                                                                                        10 (91%)                                                                                        9 (82%)                                                                                         11 (85%)                                             24 (57%)    0.055
  Diabetes, n (%)                          4 (27%)                                                                                         1 (9%)                                                                                          3 (25%)                                                                                         1 (8%)                                               12 (29%)    0.43
  Baseline eGFR (mL/min/1.73 m^2^)         43.2±13.1                                                                                       36.7±15.2                                                                                       52.7±24.8                                                                                       41.3±11.3                                            50.8±15.1   0.03
  BMI (kg/m^2^)                            22.2±5.0                                                                                        22.6±4.7                                                                                        20.2±2.3                                                                                        22.1±3.7                                             22.5±3.5    0.53
  Systolic blood pressure (mmHg)           117±7                                                                                           119±11                                                                                          121±13                                                                                          128±13                                               119±11      0.30
  Time after transplantation (years)       5.8±3.2                                                                                         7.1±4.5                                                                                         6.8±3.8                                                                                         5.8±3.1                                              5.0±3.4     0.33
  Cadaver donor, n (%)                     0                                                                                               0                                                                                               1 (8%)                                                                                          1 (8%)                                               1 (2%)      0.59
  Blood type incompatible, n (%)           4 (27%)                                                                                         5 (45%)                                                                                         4 (33%)                                                                                         6 (46%)                                              12 (29%)    0.66
  Tacrolimus-based IS, n (%)               12 (87%)                                                                                        8 (73%)                                                                                         9 (75%)                                                                                         9 (81%)                                              38 (90%)    0.51
  Trough level of tacrolimus (ng/mL)       5.0±1.0                                                                                         5.4±1.5                                                                                         5.4±1.2                                                                                         5.0±1.2                                              5.6±1.3     0.47
  MMF-based IS, n (%)                      13 (87%)                                                                                        8 (64%)                                                                                         11 (92%)                                                                                        9 (82%)                                              40 (95%)    0.38
  MMF dose (mg)                            1,173±277                                                                                       1,000±289                                                                                       932±162                                                                                         1,023±284                                            1,081±51    0.38
  mPSL dose (mg)                           2.2±1.1                                                                                         2.7±1.0                                                                                         2.6±2.6                                                                                         2.2±0.6                                              2.0±0.9     0.45
  ARB treatment, n (%)                     11 (73%)[\*](#tfn2-dddt-8-245){ref-type="table-fn"}                                             11 (100%)[\*](#tfn2-dddt-8-245){ref-type="table-fn"}                                            8 (67%)                                                                                         9 (69%)                                              17 (40%)    \<0.01
  CCB treatment, n (%)                     7 (47%)                                                                                         8 (73%)[\*](#tfn2-dddt-8-245){ref-type="table-fn"}                                              7 (58%)[\*](#tfn2-dddt-8-245){ref-type="table-fn"}                                              9 (69%)[\*](#tfn2-dddt-8-245){ref-type="table-fn"}   10 (24%)    \<0.01
  PPI treatment, n (%)                     11 (73%)                                                                                        8 (73%)                                                                                         7 (58%)                                                                                         11 (85%)                                             33 (79%)    0.60
  Statin treatment, n (%)                  1 (7%)                                                                                          5 (45%)[\*](#tfn2-dddt-8-245){ref-type="table-fn"}                                              4 (33%)                                                                                         3 (23%)                                              4 (10%)     0.03
  ESA treatment, n (%)                     3 (20%)[\*](#tfn2-dddt-8-245){ref-type="table-fn"}                                              2 (18%)[\*](#tfn2-dddt-8-245){ref-type="table-fn"}                                              0                                                                                               3 (23%)[\*](#tfn2-dddt-8-245){ref-type="table-fn"}   0           0.02

**Notes:** Values are shown as the mean ± standard deviation or n (%).

*P*\<0.05 versus NPTHU;

*P*\<0.05 versus CT.

**Abbreviations:** Cr, creatinine; PTHU, post-transplant hyperuricemia; NPTHU, non-post-transplant hyperuricemia; FX, febuxostat group; NFX, non-febuxostat group; FN, newly treated with febuxostat; FC, conversion to febuxostat; OB, observation without intervention; CT, continued conventional therapy; eGFR, estimated glomerular filtration rate; BMI, body mass index; IS, immunosuppressant; MMF, mycophenolate mofetil; mPSL, methylprednisolone; ARB, angiotensin II type 1 receptor blocker; CCB, calcium channel blocker; PPI, proton pump inhibitor; ESA, erythropoiesis-stimulating agent.

###### 

Background immunosuppressive drug regimens

                     FX         NFX                                                   NPTHU      *P*-value
  ------------------ ---------- ----------------------------------------------------- ---------- -----------
  Recipients, n      26         25                                                    42         
  Tac + MMF + mPSL   16 (62%)   13 (52%)[\*](#tfn6-dddt-8-245){ref-type="table-fn"}   35 (84%)   0.02
  Tac + MMF          0          1 (4%)                                                2 (5%)     0.54
  Tac + Mz + mPSL    4 (15%)    4 (16%)                                               1 (2%)     0.10
  CyA + MMF + mPSL   4 (15%)    5 (20%)                                               1 (5%)     0.14
  CyA + MMF          1 (4%)     1 (4%)                                                1 (2%)     0.91
  CyA + Mz + mPSL    1 (4%)     1 (4%)                                                0          0.43
  CyA + Mz           0          0                                                     1 (2%)     0.56

**Notes:** Values are shown as n (%).

*P*\<0.05 versus NPTHU.

**Abbreviations:** FX, febuxostat group; NFX, non-febuxostat group; NPTHU, non-post-transplant hyperuricemia; Tac, tacrolimus; MMF, mycophenolate mofetil; mPSL, methylprednisolone; CyA, cyclosporine; Mz, mizoribine.

###### 

Effect of febuxostat on serial serum uric acid concentrations (mg/dL)

          Baseline                                             1 month                                              3 months                                             6 months                                             12 months
  ------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  FN      8.4±0.3[†](#tfn10-dddt-8-245){ref-type="table-fn"}   6.2±0.3[\*](#tfn9-dddt-8-245){ref-type="table-fn"}   6.4±0.3[\*](#tfn9-dddt-8-245){ref-type="table-fn"}   6.2±0.3                                              6.1±0.3[\*](#tfn9-dddt-8-245){ref-type="table-fn"}
  FC      7.5±0.4[†](#tfn10-dddt-8-245){ref-type="table-fn"}   6.6±0.4                                              7.3±0.2                                              6.4±0.2                                              5.9±0.2[\*](#tfn9-dddt-8-245){ref-type="table-fn"}
  OB      7.7±0.2[†](#tfn10-dddt-8-245){ref-type="table-fn"}   7.7±0.3                                              7.7±0.3[†](#tfn10-dddt-8-245){ref-type="table-fn"}   7.2±0.3                                              7.6±0.4[†](#tfn10-dddt-8-245){ref-type="table-fn"}
  CT      6.3±0.3                                              6.9±0.4                                              6.4±0.3                                              6.4±0.4                                              6.4±0.3
  NPTHU   5.6±0.2[\*](#tfn9-dddt-8-245){ref-type="table-fn"}   5.8±0.2[\*](#tfn9-dddt-8-245){ref-type="table-fn"}   5.8±0.2[\*](#tfn9-dddt-8-245){ref-type="table-fn"}   5.7±0.2[\*](#tfn9-dddt-8-245){ref-type="table-fn"}   5.6±0.2[\*](#tfn9-dddt-8-245){ref-type="table-fn"}

**Notes:** Values are shown as the mean ± standard deviation.

*P*\<0.05 versus OB,

*P*\<0.05 versus CT.

**Abbreviations:** FN, newly treated with febuxostat; FC, conversion to febuxostat; OB, observation without intervention; CT, continued conventional therapy; NPTHU, non-post-transplant hyperuricemia.
